Delayed
Japan Exchange
02:00:00 2024-06-17 am EDT
5-day change
1st Jan Change
2,972
JPY
+1.71%
-4.44%
-9.11%
Mochida Pharmaceutical Provides Earnings Guidance for the Financial Year 2017
April 06, 2017 at 09:44 am EDT
Mochida Pharmaceutical provided earnings guidance for the financial year 2017. For the year, the company aims to earn sales of JPY 107 billion under its new three-year business plan. The company is also aiming for group operating profit of JPY 10 billion in financial year 2017.
Hidehiro Imatsu named president of Goldman Sachs Japan
Apr. 25
RE
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
Mar. 21
CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 1,080,000 shares, representing 2.97% for ¥3,485.1 million.
Mar. 18
CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Feb. 05
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
Jan. 04
CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Nov. 02
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
23-10-02
CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
23-08-04
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
23-07-03
CI
Mochida Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-15
CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
23-05-15
CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,080,000 shares, representing 2.96% for ¥3,500 million.
23-05-15
CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
23-05-14
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.
23-03-23
CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 1, 2022, has closed with 1,036,200 shares, representing 2.78% for ¥3,499.72 million.
23-03-21
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.
23-01-04
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.
22-10-03
CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million.
22-08-01
CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
22-07-31
CI
PuREC Co., Ltd. announced that it has received ¥700 million in funding from Mochida Pharmaceutical Co., Ltd., The San-in Godo Bank, Ltd., The Gogin Capital Co. Ltd. and another investor
22-03-28
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 5, 2021.
22-03-23
CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 5, 2021, has expired with 698,600 shares, representing 1.83% for ¥2,499.65 million.
22-03-21
CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 5, 2021.
22-01-05
CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 830,000 shares, representing 2.17% for ?2,500 million.
21-11-05
CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
21-11-04
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.
More about the company
1st Jan change
Capi.
-9.11% 658M +41.73% 630B -7.15% 350B +18.77% 328B +8.79% 298B +17.72% 246B +0.29% 225B +10.40% 218B +3.68% 160B -4.38% 156B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1